v3.26.1
Disaggregated Revenues (Tables)
3 Months Ended
Mar. 31, 2026
Disaggregation of Revenue [Abstract]  
Schedule of Disaggregation of Revenue by Nature
The following table provides information regarding total revenues (dollars in thousands):
Three Months Ended
March 31,
20262025
(unaudited)
Net product sales
Qelbree$77,843 $64,745 
GOCOVRI35,240 30,689 
Trokendi XR9,479 12,801 
ONAPGO8,375 — 
APOKYN7,728 14,976 
Oxtellar XR7,422 10,198 
Other(1)
4,666 8,579 
Total net product sales150,753 141,988 
Collaboration revenue (ZURZUVAE)(2)
27,643 — 
Royalty, licensing, and other revenues29,309 7,836 
Total revenues$207,705 $149,824 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
(2) Includes the Company's proportionate share of net sales of ZURZUVAE.